Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Gastric cancer
2016 Standout
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
Why do cancers have high aerobic glycolysis?
2004 Standout
Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage
2008 StandoutNobel
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma
2004
Hepatocellular carcinoma
2003 Standout
Pancreatic cancer
2004 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Renal cell carcinoma
2009
Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
2010
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
2016
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Chemotherapy for advanced gastric cancer
2010
Colorectal cancer
2013 Standout
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
2007
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Chronic kidney disease
2011 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
2003
Management of Hepatocellular Carcinoma *
2005 Standout
Cetuximab for the Treatment of Colorectal Cancer
2007
von Hippel-Lindau disease
2003 Standout
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
2009
Clinical opportunities and challenges in targeting tumour dormancy
2012
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
1996 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Renal-Cell Carcinoma
2005
Novel approaches in the therapy of metastatic renal cell carcinoma
2005
Capecitabine: A review
2005
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Prevention of Venous Thromboembolism
2004 Standout
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
2011
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
2004
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
2002 Standout
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1999
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
2000
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Gastric cancer
2020 Standout
Prevention of Venous Thromboembolism
2008 Standout
Pancreatic Cancer
2010 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Renal cell carcinoma: Current status and emerging therapies
2007
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Immunotherapy for pancreatic cancer — science driving clinical progress
2005
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy
2007
Treatment for renal cancer: are we beyond the cytokine era?
2006
Pancreatic cancer
2011 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
2006
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
2006
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy.
2002
Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients
2006
Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients
1985 Standout
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
2004
Decision aids for people facing health treatment or screening decisions
2017 Standout
Immunotherapy for renal cell cancer in the era of targeted therapy
2008
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
2003
Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma
2004
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy
2011
Part 8: Post–Cardiac Arrest Care
2015 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle?
2003
Phase I study of ftorafur, an analog of 5-fluorouracil
1975
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
2010 Standout
Sunitinib Efficacy Against Advanced Renal Cell Carcinoma
2007
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
2009
Works of A. Garin being referenced
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin
2002
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
2001
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
2005
Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy
2004
Gemzar (GEM) + Mitimycin C (MMC) in patients with advanced pancreatic cancer (APC)
1999
Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses
2009
Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy
2004
Results of treatment of malignant tumors with ftorafur
1972